APP and Alzheimer disease: This consideration is particularly critical, as amyloid precursor protein (APP)–targeting small interfering RNA (siRNA) therapeutics are currently undergoing clinical evaluation for the treatment of AD and cerebral amyloid angiopathy (CAA).37